文献速递炎症性肠病

第二种JAK抑制剂治疗溃疡性结肠炎的有效性与安全性:J2J多中心研究

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study.
PubMed 文献 · Aliment Pharmacol Ther · 2025-05-22

这项多中心回顾性观察性队列纳入169例中重度溃疡性结肠炎患者,在第一种JAK抑制剂失败或不耐受后换用第二种JAK抑制剂。第8-14周无激素临床缓解(SFCR)共81/169例,乌帕替尼组58/105、非戈替尼组18/54、托法替布组5/10(p=0.03);多因素分析中乌帕替尼较非戈替尼独立关联更高的SFCR几率(OR=3.15,95%CI 1.52-6.79)。第二种JAK抑制剂诱导后约半数患者获临床缓解且耐受性良好。

要点

  • 第二种JAK抑制剂诱导后约半数溃疡性结肠炎患者达无激素临床缓解。
  • 第8-14周SFCR:乌帕替尼58/105、非戈替尼18/54、托法替布5/10(p=0.03)。
  • 乌帕替尼较非戈替尼独立关联更高SFCR几率(OR=3.15,95%CI 1.52-6.79)。

核心结论

  • 第二种JAK抑制剂诱导后约半数患者获临床缓解,且耐受性良好。

研究设计与样本

  • 多中心、回顾性、观察性队列,纳入中重度溃疡性结肠炎患者,在第一种JAK抑制剂失败或不耐受后接受第二种JAK抑制剂。
  • 共169例患者来自28个参与中心,第二种JAK抑制剂为乌帕替尼105例、非戈替尼54例、托法替布10例。

主要发现

  • 第8-14周总体81/169例达无激素临床缓解(SFCR)。
  • 第8-14周SFCR:乌帕替尼组58/105 vs 非戈替尼组18/54 vs 托法替布组5/10(p=0.03)。
  • 多因素分析中,乌帕替尼较非戈替尼独立关联更高的SFCR几率(OR=3.15,95%CI 1.52-6.79)。
  • 中位随访96天,6个月药物持续率:乌帕替尼72.8%、非戈替尼57.2%、托法替布66.7%(p=0.099)。
  • 24.3%(41/169)患者发生至少一次不良事件,9例(5%)因不良事件停药;未报告死亡、肿瘤或主要急性心血管事件。

关键数值与推荐

  • SFCR定义为部分Mayo评分≤2且各单项分项不超过1。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While three Janus kinase inhibitors (JAKi) have demonstrated efficacy in ulcerative colitis (UC), scarce data exist regarding JAKi intraclass switching. AIM: To evaluate the effectiveness and safety of a second JAK inhibitor in UC. METHODS: This was a multicentre, retrospective, observational cohort including patients with moderate to severe UC who received a second-line of JAKi after failure or intolerance of a first. The primary outcome was steroid-free clinical remission (SFCR) at Weeks 8-14, defined as a partial Mayo score of 2 or less with no individual sub-score above 1. RESULTS: Among the 169 patients from 28 participating centres, 105 received upadacitinib, 54 filgotinib and 10 tofacitinib as a second-line of JAKi. Overall, 81/169 achieved SFCR at Weeks 8-14: 58/105 with upadacitinib, 18/54 with filgotinib and 5/10 with tofacitinib (p = 0.03). In the multivariate analysis, upadacitinib was independently associated with higher odds of SFCR than filgotinib (OR = 3.15, 95% CI [1.52-6.79]). With a median follow-up duration of 96 days, drug persistence at 6 months was 72.8% with upadacitinib, 57.2% with filgotinib and 66.7% with tofacitinib (p = 0.099). 24.3% of patients (41/169) experienced at least one adverse event leading to treatment withdrawal in 9 patients (5%). No cases of death, cancer, or major acute cardiovascular events were reported. CONCLUSION: A second-line of JAKi provided clinical remission in about half of patients after induction, and was well tolerated.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Osty M, Altwegg R, Serrero M, et al. Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study. Aliment Pharmacol Ther. 2025. PMID: 40400411. doi:10.1111/apt.70199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。